- •
Resilience against GLP-1 headwinds - While weight-loss drugs were feared to be an existential threat, data suggests they are often complementary to sleep apnea therapy rather than a total replacement.
“The market overreacted to the GLP-1 threat, forgetting that a more health-conscious population actually leads to higher diagnosis rates, not lower device demand.”
- •
Dominance through competitor defaults - ResMed continues to entrench its market leadership as it capitalizes on the prolonged product recall struggles of its primary rival, Philips.
- •
Shift to high-margin recurring revenue - The investment thesis is evolving from hardware sales to a digital-first model focused on patient monitoring software and consistent mask replacement cycles.
“The market overreacted to the GLP-1 threat, forgetting that a more health-conscious population actually leads to higher diagnosis rates, not lower device demand.”